Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Although numerical increases were identified in fasting and postprandial IL-6 values at 9 and 12 months compared to baseline, the changes did not reach statistical significance ( Table 3 ).

also in 111,027 other papers

Fasting GIP demonstrated an increasing trend at 9 months, and the improvement was significant at 12 months ( Table 3 ).

also in 63,971 other papers

Increases in this analyte after the initiation of ADT were highly significant, and metformin significantly attenuated this increase.

also in 132,142 other papers